The National Institute for Health and Clinical Excellence is recommending an innovative deal for an anti-cancer drug. It says patients with multiple myeloma who show a full or partial response to the drug Velcade should be kept on it and be funded by the NHS.
Those showing a minimal response or no response should be taken off it - with all drug costs refunded by the manufacturer, Janssen-Cilag.
Andy Cowper on workforce as the biggest issue facing the NHS currently
Anita Charlesworth, Candace Imison and Richard Murray look in detail at solutions across the different policy levers for workforce, including training, pay, staff retention and skill mix
An estimated extra quarter of a million patients a year could be referred to the private sector under new waiting list rules, HSJ analysis has revealed.
We are aware that some of our users are experiencing problems accessing hsj.co.uk.
To protect your security as hsj.co.uk upgrades to a new platform, your existing password will no longer work.
Financial penalties are being lifted from high-profile standards including cancer and elective waiting times, so far without attracting much attention. How is this happening? And will it work, asks Rob Findlay
No comments yet